GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » TherapeuticsMD Inc (NAS:TXMD) » Definitions » Cyclically Adjusted FCF per Share

TherapeuticsMD (TherapeuticsMD) Cyclically Adjusted FCF per Share : $-23.37 (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is TherapeuticsMD Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

TherapeuticsMD's adjusted free cash flow per share for the three months ended in Dec. 2023 was $-0.449. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-23.37 for the trailing ten years ended in Dec. 2023.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 22.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 37.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of TherapeuticsMD was 49.30% per year. The lowest was -48.90% per year. And the median was -10.70% per year.

As of today (2024-04-29), TherapeuticsMD's current stock price is $1.86. TherapeuticsMD's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $-23.37. TherapeuticsMD's Cyclically Adjusted Price-to-FCF of today is .

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of TherapeuticsMD was 26.00. The lowest was 0.62. And the median was 1.42.


TherapeuticsMD Cyclically Adjusted FCF per Share Historical Data

The historical data trend for TherapeuticsMD's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TherapeuticsMD Cyclically Adjusted FCF per Share Chart

TherapeuticsMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -158.51 -51.09 -22.90 -23.45 -23.37

TherapeuticsMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -23.45 -23.71 -23.64 -23.64 -23.37

Competitive Comparison of TherapeuticsMD's Cyclically Adjusted FCF per Share

For the Drug Manufacturers - Specialty & Generic subindustry, TherapeuticsMD's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TherapeuticsMD's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, TherapeuticsMD's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where TherapeuticsMD's Cyclically Adjusted Price-to-FCF falls into.



TherapeuticsMD Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, TherapeuticsMD's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.449/129.4194*129.4194
=-0.449

Current CPI (Dec. 2023) = 129.4194.

TherapeuticsMD Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201403 -3.044 99.695 -3.952
201406 -3.503 100.560 -4.508
201409 -3.757 100.428 -4.842
201412 -5.022 99.070 -6.560
201503 -5.869 99.621 -7.625
201506 -7.206 100.684 -9.263
201509 -5.214 100.392 -6.722
201512 -4.794 99.792 -6.217
201603 -5.020 100.470 -6.466
201606 -4.027 101.688 -5.125
201609 -4.832 101.861 -6.139
201612 -4.072 101.863 -5.174
201703 -5.223 102.862 -6.571
201706 -4.525 103.349 -5.666
201709 -4.029 104.136 -5.007
201712 -4.984 104.011 -6.202
201803 -4.576 105.290 -5.625
201806 -5.830 106.317 -7.097
201809 -11.925 106.507 -14.490
201812 -6.002 105.998 -7.328
201903 -8.056 107.251 -9.721
201906 -10.718 108.070 -12.835
201909 -5.705 108.329 -6.816
201912 -13.660 108.420 -16.306
202003 -7.286 108.902 -8.659
202006 -10.363 108.767 -12.331
202009 -6.294 109.815 -7.418
202012 -5.380 109.897 -6.336
202103 -5.589 111.754 -6.472
202106 -3.378 114.631 -3.814
202109 -4.548 115.734 -5.086
202112 -4.801 117.630 -5.282
202203 -2.099 121.301 -2.239
202206 -2.377 125.017 -2.461
202209 1.914 125.227 1.978
202212 2.784 125.222 2.877
202303 -0.892 127.348 -0.907
202306 -0.332 128.729 -0.334
202309 -0.563 129.860 -0.561
202312 -0.449 129.419 -0.449

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


TherapeuticsMD  (NAS:TXMD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of TherapeuticsMD was 26.00. The lowest was 0.62. And the median was 1.42.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


TherapeuticsMD Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of TherapeuticsMD's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


TherapeuticsMD (TherapeuticsMD) Business Description

Industry
Traded in Other Exchanges
Address
951 Yamato Road, Suite 220, Boca Raton, FL, USA, 33431
TherapeuticsMD Inc is a major drug manufacturing with a focus on creating and commercializing products targeted exclusively for women. The company intends to commercialize advanced hormone therapy pharmaceutical products. TherapeuticsMD's drug candidates that have completed clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and discomfort. The company relies on third parties for the production of clinical and commercial quantities of its drug candidates.
Executives
Marlan D Walker officer: General Counsel 951 YAMATO ROAD, SUITE 220, BOCA RATON FL 33431
Joseph Ziegler officer: Principal Financial Officer 1051 HILLSBORO MILE, PH2, HILLSBORO BEACH FL 33062
Michael C Donegan officer: CAO and VP of Finance 6800 BROKEN SOUND PARKWAY NW, THIRD FLOOR, BOCA RATON FL 33487-3507
Rubric Capital Management Lp 10 percent owner 155 EAST 44TH ST, SUITE 1630, NEW YORK NY 10017
Brian Bernick director 951 BROKEN SOUND PARKWAY NW, SUITE 320, BOCA RATON FL 33487
Gail K Naughton director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Mark A Glickman officer: Chief Business Officer C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Justin Hunter Roberts director C/O RUBRIC CAPTIAL MANAGEMENT LP, 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Tommy G Thompson director 7711 CARONDELET, ST. LOUIS MO 63105
Karen Ling director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Paul Bisaro director
Angus C. Russell director C/O INTERMUNE, INC., 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Jules A. Musing director 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
David Efraim Rosen 10 percent owner 155 EAST 44TH ST., SUITE 1630, NEW YORK NY 10017
Collins Cooper C. director 33219 FOREST WEST DRIVE, MAGNOLIA TX 77354

TherapeuticsMD (TherapeuticsMD) Headlines

From GuruFocus

SHAREHOLDER ALERT: Weiss Law Investigates TherapeuticsMD, Inc.

By PRNewswire PRNewswire 06-30-2022

TherapeuticsMD Announces First Quarter 2023 Financial Results

By Business Wire Business Wire 05-15-2023

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

By Business Wire Business Wire 08-01-2022